Immediate vs delayed kidney removal with immunotherapy for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares removing the kidney tumor right away versus waiting, while both groups receive the immunotherapy drugs ipilimumab and nivolumab. It is for people with advanced kidney cancer that has spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have advanced clear cell kidney cancer that has spread to other organs.
- You are in good enough health to be up and active (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your kidney tumor can be removed with surgery.
- Your cancer is classified as intermediate or poor risk by standard criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
Hear when a new Metastatic Renal Cell Carcinoma ( mRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.